LYFE Capital

Verdiva Bio is a company creating cutting-edge treatments that improve results for patients with obesity, cardiometabolic diseases, and associated problems by making treatment options more patient-friendly. Verdiva Bio operates in the cardiometabolic health sector, creating innovative treatments designed to improve the quality of care for patients facing these health issues.

CytoTronics specializes in the design and development of advanced cell culture plates that incorporate high-density electronic systems. Its semiconductor-based technology facilitates the visualization of live cell functions at scale, providing researchers with real-time data on cellular behavior. This capability enhances the study of complex biological processes, which may lead to significant advancements in drug discovery and personalized medicine. By enabling a deeper understanding of cell biology, CytoTronics aims to support innovative research and foster breakthroughs in various scientific fields.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

Magair Chemical is a chemical synthesis CRO that was founded by Magera Technology. It is committed to using automated and intelligent platforms to provide new drug R&D customers with a new generation of chemical synthesis CRO services, significantly shortening the delivery of chemical synthesis links in the new drug R&D cycle, and significantly reducing the costs associated with chemical synthesis, removing pharmaceutical synthesis's current reliance on manual operations.

Elite Technology is a company that specializes in the development of chromatographic techniques, workstations, and high-performance liquid chromatography equipment for analysis, preparation, and industrial production.

HC Scientific (Chengdu) L.L.C., founded in early 2016, focuses on developing intelligent solutions within the life sciences sector. The company aims to be a trusted partner for global clients by offering innovative products, including genetic testing instruments, reagents, and software. These products are primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is recognized as a national high-tech enterprise, emphasizing autonomous research and the development of intellectual property. The company participates in significant national and provincial scientific initiatives and is supported by a team of experts, including returning PhDs. Its product offerings streamline complex tasks for life science practitioners, delivering high-throughput, automated, and cost-effective genetic testing solutions while creating value for collaborative partners.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.

Noah Medical is a manufacturer of medical robotic devices aimed at enhancing the diagnosis and treatment of patients in various healthcare settings. The company's innovative devices facilitate early diagnoses and treatments, particularly in advanced clinical environments. By enabling hospitals to address medical issues promptly, Noah Medical's technology contributes to improved patient outcomes and minimizes scarring associated with procedures.

Genepoint Biological Technology (China) Co., Ltd. specializes in the manufacture of devices for cryogenic biomaterial storage and handling, aimed at supporting life sciences research. Based in Shanghai, the company offers a range of products, including Automated Cryo-Bio Storage systems, Plugged Hybrid Cryo-Storage units, and LIN Vapor Freezers. These innovative solutions are designed to facilitate biotechnology research and development by enhancing the efficiency of sample storage operations. Genepoint is committed to advancing cryogenic robotic systems, enabling researchers to manage biological samples effectively and conduct experiments with greater ease.

Dieshi-DISC is a soft hydrophilic contact lens that was developed and marketed. Their new type of hydrophilic contact lens can delay the progression of myopia. After wearing the lens, the retina will produce a clear image, and there will be out-of-focus or blurred images in front of the patient.

iECURE is a biotechnology company focused on developing gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. The company employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted therapeutic interventions without being limited by specific genetic mutations. Its initial programs concentrate on addressing metabolic "loss of function" disorders, which often have significant unmet medical needs. Through its innovative approach, iECURE aims to provide effective treatments for devastating diseases that currently lack viable options.

Edgene Biot is a life sciences company focused on advancing biotechnology through innovative genetic engineering techniques. It specializes in digital precision breeding technology and offers a range of platforms, including gene editing, molecular biology, and high-throughput genetic transformation, alongside a gene bank and a detection and analysis platform. These resources enable clients to enhance environmental control throughout the cultivation process of genetically transformed crops. Edgene Biot aims to lead the market in the application of digital biotechnology in biological breeding by scaling production and accelerating the transformation of achievements, informed by a comprehensive understanding of both domestic and international biotechnology trends and the growth of the biological breeding industry.

ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and early drug discovery services. Founded in 2010, the company focuses on the development of ion channel-related pharmaceuticals, particularly targeting the neuronal and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel profiling, cardiac safety panels, brain slice screening, and various molecular biology applications. The company has established proprietary ion channel cell lines for both voltage-gated and ligand-gated channels. Additionally, it maintains a diverse platform for target-based panel screening, supporting drug discovery across multiple therapeutic areas such as immunology, oncology, and CNS diseases. ICE Bioscience is committed to enhancing the drug discovery process through effective communication and flexible collaboration models, aiming to identify and validate drug targets and streamline the progression from compound screening to preclinical candidate selection.

Biointron, founded in 2012 and based in Shanghai, China, specializes in the development of recombinant antibody technology and offers contracted research organization (CRO) services. The company focuses on accelerating the antibody discovery process by providing a comprehensive range of services, including rapid expression platforms, antibody sequencing, and labeling tools. Through its innovative technology, Biointron achieves high-throughput recombinant antibody production, supplying customers with high-quality and cost-effective recombinant protein and antibody reagents.

Baiying Bio offers economic recombinant protein and antibody reagents and is a CRO vendor for life science researchers and biopharma companies. They provide services including HTP recombinant antibody and VHH production, bispecific antibody production, antibody humanization, VHH library generation, hybridoma sequencing, protein expression in mammalian cells, large-scale antibody production, and more. They delivered tens of thousands of recombinant antibodies to customers.

MobiDrop specializes in developing microfluidic technologies aimed at enhancing life sciences and precision medicine. The company creates advanced instruments, comprehensive assays, and user-friendly software designed for digital droplet PCR (ddPCR) and single-cell multi-omic platforms. MobiDrop is dedicated to innovating molecular diagnostics and life science research by improving the quality of diagnosis and testing. Its product portfolio includes integrated machine platforms, microfluidic detection chips, and supporting reagents, which find applications in molecular diagnostics, cancer screening, and drug research and development. Through these offerings, MobiDrop contributes significantly to the advancement of life science research and in vitro diagnostics.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

Starna Therapeutics is focused on developing innovative drugs that utilize RNA technology at their core. The company possesses a proprietary RNA and organ-selective delivery technology platform, which underpins its extensive research and development pipeline. This pipeline addresses unmet clinical needs in various areas, including vaccines for infectious diseases, tumor immunology, and metabolic disorders. By leveraging its independent intellectual property rights, Starna Therapeutics aims to advance the field of RNA-based therapeutics and contribute to significant advancements in healthcare.

Boyue Bio focuses on the development of biomedical raw materials and integrated solutions. The company's four product lines include Bioactive Materials, Nanometer Microspheres, Chromatographic Products, and Integrated Solutions. Boyue Bio seeks to be a major provider of total solutions and core raw materials for the biomedical industry.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

SUSTAO is a manufacturer of consumables that meet the technical requirements of medical robots.

Elixir Clinical Research is a technology-driven contract research organization (CRO) that specializes in providing comprehensive clinical research services. The company aims to facilitate the rapid launch of new drugs by offering a range of services, including bioequivalence studies, Phase I-IV clinical trials, real-world research, and final application registration. Elixir also supports clients in designing research programs, developing medical strategies, managing regulatory processes, overseeing clinical centers, and handling data management and biostatistics. By delivering qualified and effective clinical research solutions, Elixir assists pharmaceutical companies in navigating the complexities of drug development and regulatory approval.

Shenji Bio focuses on the research and development of fundamental raw materials such as nucleosides, nucleotides, diagnostic antigens, and antibodies. As a development direction, Shenji Bio provides cost-effective products and addresses clinical unmet needs. It has gradually entered the upstream core raw material fields of IVD, mRNA, CGT, and other industries, and has established a high-quality key common technology platform to provide overall solutions for the life science field's development.

Levostar is a biotechnology company focused on the development and manufacture of cell and gene therapy products. It provides innovative technologies and comprehensive solutions for the cell gene therapy industry. The company offers clinical testing services for various therapy platforms, including viral vector platforms and mRNA vaccines. Additionally, Levostar specializes in Good Manufacturing Practice (GMP)-level production processes and quality control methods for plasmids and mRNAs. By delivering these services and products, Levostar aims to accelerate research and development in gene cell therapy and mRNA drug development, contributing to advancements in the biotechnological field.

CellOrigin Biotech specializes in the development of innovative therapeutics using induced pluripotent stem cells (iPSCs) to create innate immune cells. The company is dedicated to advancing immune cell technology aimed at treating solid tumors. Its research focuses on the generation of gene-manipulated, clinically applicable iPSCs and the establishment of a clinical iPSC bank. Additionally, CellOrigin Biotech is developing an efficient platform for differentiating iPSCs into mature stem cells, which enhances their potential for therapeutic applications. Through these efforts, the company aims to contribute significantly to the field of cancer treatment.

Molecular Assemblies, Inc. is a San Diego-based company specializing in enzymatic DNA synthesis technology, which facilitates the development of DNA-based products across various industries. Founded in 2013, the company focuses on creating long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner, inspired by natural processes. Its technology has applications in industrial synthetic biology, personalized therapeutics, precision diagnostics, information storage, nanotechnology, and DNA electronics. The firm boasts a skilled executive and scientific team, supported by a robust intellectual property portfolio. Molecular Assemblies has garnered investments from a range of venture capital sources, indicating strong interest in its innovative approach to DNA synthesis.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

Genepoint Biological Technology (China) Co., Ltd. specializes in the manufacture of devices for cryogenic biomaterial storage and handling, aimed at supporting life sciences research. Based in Shanghai, the company offers a range of products, including Automated Cryo-Bio Storage systems, Plugged Hybrid Cryo-Storage units, and LIN Vapor Freezers. These innovative solutions are designed to facilitate biotechnology research and development by enhancing the efficiency of sample storage operations. Genepoint is committed to advancing cryogenic robotic systems, enabling researchers to manage biological samples effectively and conduct experiments with greater ease.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.

Hugo Biotech is a developer of advanced microbial sequencing technology, specializing in high-throughput sequencing and genomic analysis. The company has sequenced nearly 20,000 clinical samples for over 300 leading hospitals in China. Its innovative approach allows for the rapid and precise identification of pathogenic microorganisms in clinical samples, eliminating the need for traditional culturing methods and specific amplification techniques. This capability supports healthcare professionals in making timely and informed decisions regarding patient treatment.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.

Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.

MingMed is a Chinese pharmaceutical company focused on independent drug research and development, with a diverse product pipeline that includes ophthalmic drugs, small molecule immune drugs, and cell therapies utilizing gene editing. The company's offerings extend to recombinant protein botulinum toxin, tumor immune drugs, and immunotherapy for pets. MingMed is dedicated to producing innovative solutions across various fields, including ophthalmology, medical aesthetics, and veterinary medicine, with several of its promising drug candidates having reached the clinical stage. The company's commitment to developing First-in-Class innovative drugs positions it competitively in the global pharmaceutical market.

HC Scientific (Chengdu) L.L.C., founded in early 2016, focuses on developing intelligent solutions within the life sciences sector. The company aims to be a trusted partner for global clients by offering innovative products, including genetic testing instruments, reagents, and software. These products are primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is recognized as a national high-tech enterprise, emphasizing autonomous research and the development of intellectual property. The company participates in significant national and provincial scientific initiatives and is supported by a team of experts, including returning PhDs. Its product offerings streamline complex tasks for life science practitioners, delivering high-throughput, automated, and cost-effective genetic testing solutions while creating value for collaborative partners.

Hugo Biotech is a developer of advanced microbial sequencing technology, specializing in high-throughput sequencing and genomic analysis. The company has sequenced nearly 20,000 clinical samples for over 300 leading hospitals in China. Its innovative approach allows for the rapid and precise identification of pathogenic microorganisms in clinical samples, eliminating the need for traditional culturing methods and specific amplification techniques. This capability supports healthcare professionals in making timely and informed decisions regarding patient treatment.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

neoX BIOTECH is a biotechnology company established in 2018 and located in Beijing, China. The company specializes in the development of antigen-based cancer vaccines, leveraging a combination of artificial intelligence and biophysics to enhance drug research and development. neoX BIOTECH has created a neoantigen prediction and TCR screening platform that facilitates the discovery of effective macromolecular and multispecific drugs, particularly within the immuno-oncology sector. By characterizing protein-protein interactions, the company aims to advance early therapeutic discovery, ultimately improving treatment options for cancer patients.

Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.

General Biosystems is a biotechnology company that focuses on high-quality, high-throughput, automated production of DNA constructs. The company through its passion in understanding how genetic information is stored and programmed in the DNA develops innovative technologies and instruments to program and physically write or print new genetic codes. The new codes will create blueprints for new or enhanced biological and biological functions.

Zhenyi Yiliao is a medical enterprise focusing on structural heart disease.

Just Medical is a developer and manufacturer of orthopedic medical devices, specializing in artificial implants such as hip and knee joints, as well as internal fixation products and surgical instruments. The company emphasizes research and development in orthopedics, aiming to enhance surgical efficiency and improve the quality of orthopedic treatment. Just Medical is dedicated to providing safe and effective medical products and services, continually refining its product systems to alleviate patient pain and support healthcare professionals in their surgical procedures.

Molecular Assemblies, Inc. is a San Diego-based company specializing in enzymatic DNA synthesis technology, which facilitates the development of DNA-based products across various industries. Founded in 2013, the company focuses on creating long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner, inspired by natural processes. Its technology has applications in industrial synthetic biology, personalized therapeutics, precision diagnostics, information storage, nanotechnology, and DNA electronics. The firm boasts a skilled executive and scientific team, supported by a robust intellectual property portfolio. Molecular Assemblies has garnered investments from a range of venture capital sources, indicating strong interest in its innovative approach to DNA synthesis.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

ImmuneOnco Biopharma, established in June 2015 in Zhangjiang High-Tech Park, Shanghai, is an early-stage biopharmaceutical company focused on developing innovative cancer immunotherapy products. The company aims to combat cancer by reversing immune suppression caused by cancer cells and actively targeting their eradication. ImmuneOnco employs a systematic approach to leverage both the innate and adaptive immune systems, which positions it among the few biotechnology firms globally pursuing this strategy. The company has developed a diverse pipeline of 14 drug candidates, with eight currently undergoing clinical programs. This extensive portfolio underscores ImmuneOnco's deep understanding of cancer biology and immunology, as well as its capability to translate scientific research into viable therapeutic options.

ABclonal Inc. is a life science research and diagnostic reagents provider based in Woburn, Massachusetts, founded in 2016. The company specializes in offering a variety of biological research agents and services, including next generation sequencing library preparation kits, molecular biology products, catalog antibodies, catalog proteins, ELISA kits, and western blot tools and reagents. In addition to its extensive product range, ABclonal provides customized services related to peptides, antibodies, and proteins. The company distributes its products through a network of distributors across Europe, Asia, North America, and Oceania, aiming to enhance the quality of life science research with its high-quality offerings.

Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.

Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company based in Cleveland, Ohio, founded in 2013. The company specializes in the development and commercialization of non-invasive cancer diagnostic tests, focusing on blood-based assays for prostate, breast, and ovarian cancers, with plans to expand into lung cancer and certain neurological diseases. Cleveland Diagnostics employs proprietary solvent interaction analysis technology to investigate protein biomarkers at the structural level, enhancing the specificity and accuracy of its tests. The company has formed a strategic collaboration with Genomic Health to further its mission of improving cancer diagnostics and screening.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment, primarily serving cancer and cell biology research. The company offers a range of products including the Cytek Aurora and Cytek Northern Lights flow cytometers, the DxP Athena flow cytometry system that utilizes advanced technology to resolve dim populations in a multicolor format, and the QbSure quality control program for assessing cytometer performance. Additionally, Cytek provides proprietary cFluor reagents designed to optimize instrument performance in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company, formerly known as Cytoville, Inc., rebranded to Cytek Biosciences, Inc. in August 2015.

ImmuneOnco Biopharma, established in June 2015 in Zhangjiang High-Tech Park, Shanghai, is an early-stage biopharmaceutical company focused on developing innovative cancer immunotherapy products. The company aims to combat cancer by reversing immune suppression caused by cancer cells and actively targeting their eradication. ImmuneOnco employs a systematic approach to leverage both the innate and adaptive immune systems, which positions it among the few biotechnology firms globally pursuing this strategy. The company has developed a diverse pipeline of 14 drug candidates, with eight currently undergoing clinical programs. This extensive portfolio underscores ImmuneOnco's deep understanding of cancer biology and immunology, as well as its capability to translate scientific research into viable therapeutic options.

Shenqi Medical specializes in the research and manufacturing of innovative medical devices, primarily catering to the healthcare sector in China. The company offers a diverse range of products aimed at addressing cardiovascular issues, structural heart disease, and peripheral and neurovascular conditions. By focusing on minimally invasive surgical technologies, Shenqi Medical aims to enhance the safety and reliability of cardiovascular procedures, ultimately improving patient outcomes.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Just Medical is a developer and manufacturer of orthopedic medical devices, specializing in artificial implants such as hip and knee joints, as well as internal fixation products and surgical instruments. The company emphasizes research and development in orthopedics, aiming to enhance surgical efficiency and improve the quality of orthopedic treatment. Just Medical is dedicated to providing safe and effective medical products and services, continually refining its product systems to alleviate patient pain and support healthcare professionals in their surgical procedures.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.

Aohua is a global provider of endoscopy devices and solutions, specializing in the research, development, production, and sales of electronic endoscope equipment as well as endoscopic diagnostic and surgical consumables. Founded in 1994 and based in Shanghai, China, Aohua aims to lead in endoscope technology innovation and advance the progress of endoscopic diagnosis and treatment. The company is committed to enhancing medical practices through its advanced technological offerings in the endoscopy field.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat serious human diseases. The company specializes in host-directed anti-viral therapies, which aim to combat respiratory viral infections, including various strains of influenza and parainfluenza viruses. Its lead product candidates include Fludase, designed for the prophylaxis and treatment of respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fevers caused by pathogens such as Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a formulation technology for drug delivery using microspheres and nanospheres. Founded in 2003, the company was previously known as NexBio, Inc. before rebranding in 2011.

Laviana Pharma Co., Ltd. founded in 2005 is a high-tech enterprise. It specializes in providing process and manufacture outsourcing services (CDMO) for the pharmaceutical industry. The main scope of services covers all chemistry-related aspects of process development and transformation for the innovative drug substances and products from laboratory scale to commercialized scale, including process research, process development, process optimization, pilot production and large-scale production of intermediates, API starting materials and API (active pharmaceutical ingredient) for pre-clinical, clinical trial materials and commercialized products. It also provides CMC services for IND and NDA submission of innovative developmental drug. It has three wholly-owned subsidiary, namely, Beijing laviana Pharmatech Co., Ltd., Laviana (Tianjin) Pharmatech Development Co., Ltd., and Laviana Corporation incorporated in United States.

Baixing Pingan Yaofang is an online pharmacy. They serve vitamin C, vitamin AD, zinc, calcium, carbonate, vitamin AD, cod liver oil, calcium complex multi-vitamins, complex minerals, and kidney nourishes the kidneys and the liver, and gelatin contains folic acid.

Bondent is a provider of integrated oral medical solutions tailored for the oral health and dental industry. The company specializes in the design, development, manufacturing, and sales of oral medical equipment, creating a comprehensive ecosystem that supports dental professionals. In addition to its product offerings, Bondent provides technical training and operational management consulting services to enhance the capabilities of its clients. This multifaceted approach positions Bondent as a key player in the advancement of oral health practices.

Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.

Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.

Fuzhou Kangwei Network Technology is a management platform for blood glucose disease monitoring. They offer a data engine to provide decision support for doctors' diagnoses and treatments. Their data engine recommends diagnosis and treatment suggestions based on the patient's blood glucose data, and doctors can formulate diagnosis and treatment plans professionally and quickly according to the patient's condition.

WinnTi Medical creates medical devices through continuous product innovations and manufacturing improvements, meeting surgeons' increasing demands, and improving patients' wellness.